Creatine Supplementation In Fibromyalgia: A Randomized, Double-blind, Placebo-controlled Trial
| Effect | Increase |
| Values | When compared to the placebo group, the creatine group showed a statistically significant improvement in the mental health domain of the Short Form 36 (SF-36) health survey (a tool used to measure quality of life), but the other domains of the survey remained unaffected. SF-36 mental health domain. Mental health domain of SF-36. Creatine group showed +23.9% improvement p = 0.03 compared to placebo. |
| Trial Design | Randomized trial |
| Trial Length | 1-6 months |
| Number of Subjects | 32 |
| Sex | n/a |
| Age Range | 30-44, 45-64, 65+ |
| Body Types | Overweight, Average |
This randomized controlled trial had the subjects consume either creatine monohydrate or a placebo for 16-weeks. The participants in the creatine arm began taking 20 grams for 5 days divided into 4 equal doses, which was then followed by consuming 5 grams daily for the rest of the intervention. The placebo group was given the same protocol but consumed dextrose. Muscle function, aerobic conditioning, cognition, quality of sleep, kidney function and muscle phosphorylcreatine content was measured before and after the study.
There were improvements in leg and chest press strength and increased intramuscular phosphocreatine content. However, there were no statistically significant improvements in symptoms of fibromyalgia and quality of life.
